Sugemalimab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Sugemalimab is a monoclonal antibody used in the treatment of certain types of cancer, specifically non-small cell lung cancer (NSCLC). It is a type of immune checkpoint inhibitor that targets the PD-L1 protein, which is involved in the immune system's ability to recognize and attack cancer cells.
Mechanism of Action[edit | edit source]
Sugemalimab works by binding to the programmed death-ligand 1 (PD-L1) on the surface of tumor cells. PD-L1 is a protein that can suppress the immune system by interacting with the programmed death-1 (PD-1) receptor on T cells. By blocking this interaction, sugemalimab enhances the immune system's ability to detect and destroy cancer cells.
Clinical Use[edit | edit source]
Sugemalimab is primarily used in the treatment of non-small cell lung cancer (NSCLC). It has been shown to improve survival rates in patients with advanced stages of the disease. Clinical trials have demonstrated its efficacy in both first-line and subsequent lines of therapy.
Side Effects[edit | edit source]
Common side effects of sugemalimab include fatigue, nausea, decreased appetite, and rash. More serious side effects can include immune-mediated reactions such as pneumonitis, hepatitis, and colitis, which require careful monitoring and management.
Research and Development[edit | edit source]
Sugemalimab is developed by CStone Pharmaceuticals and has undergone several clinical trials to establish its safety and efficacy. It is part of a growing class of immunotherapy drugs that are transforming the treatment landscape for various cancers.
Regulatory Status[edit | edit source]
Sugemalimab has been approved for use in several countries for the treatment of NSCLC. It is subject to ongoing studies to explore its potential in other types of cancer and in combination with other therapies.
Also see[edit | edit source]
- Monoclonal antibody therapy
- Immune checkpoint inhibitors
- Non-small cell lung cancer
- PD-L1
- Cancer immunotherapy
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
